Affordable Access

deepdyve-link
Publisher Website

Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: A 2-year randomized, placebo-controlled, comparative study

Authors
  • Post, Marinka S.
  • van der Mooren, Marius J.
  • van Baal, W.Marchien
  • Neele, Simone J.M.
  • Netelenbos, J.Coen
  • Kenemans, Peter
Type
Published Article
Journal
American Journal of Obstetrics and Gynecology
Publisher
Elsevier
Publication Date
Jan 01, 2001
Accepted Date
May 18, 2001
Volume
185
Issue
3
Pages
557–562
Identifiers
DOI: 10.1067/mob.2001.117340
Source
Elsevier
Keywords
License
Unknown

Abstract

Objective: We sought to investigate the long-term effect of raloxifene and continuous combined hormone replacement therapy (ccHRT) on impedance to flow within the uterine artery in postmenopausal women. Study Design: A prospective, randomized, double-blind, placebo-controlled 2-year study was performed in 95 postmenopausal women. They received either 60 mg of raloxifene daily (raloxifene 60 group), 150 mg of raloxifene daily (raloxifene 150 group), ccHRT, or placebo. At baseline and thereafter every 6 months, color Doppler ultrasonography was used to measure the pulsatility index (PI) of the uterine artery. Results: After 24 months of treatment, compared with placebo, significant decreases were found in the PI in the raloxifene 150 group (P =.021) and in the ccHRT group (P =.007). In the raloxifene 150 group compared with the placebo group, after 6 and 24 months, decreases were observed in median PI of –5% and –15%, respectively, and in the ccHRT group decreases of –2% and –19%, respectively, were found. Conclusion: Long-term use of 150 mg of raloxifene daily or ccHRT reduces impedance to flow within the uterine artery. This indicates that high-dose raloxifene may exert cardiovascular protection. (Am J Obstet Gynecol 2001;185:557-62.)

Report this publication

Statistics

Seen <100 times